Liming Peng1,2, Thiago Gagliano-Jucá2, Karol M Pencina2, Srinivasan Krishnan3, Zhuoying Li2, Russell P Tracy4, Ravi Jasuja2, Shalender Bhasin1,2. 1. Brigham Research Assay Core Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 2. Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 3. Billerica, Massachusetts, USA. 4. Larner College of Medicine, University of Vermont, Burlington, USA.
Abstract
BACKGROUND: Growth and differentiation factor (GDF)-11 controls embryonic development and has been proposed as an antiaging factor. GDF-8 (myostatin) inhibits skeletal muscle growth. Difficulties in accurately measuring circulating GDF-11 and GDF-8 have generated controversy. METHODS: We developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for simultaneous measurement of circulating GDF-8 and GDF-11 that employs denaturation, reduction, and alkylation; cation-exchange solid-phase extraction; tryptic digestion; followed by separation and quantification using 2 signature peptides for multiple reaction monitoring and C-terminal [13C615N4]-Arg peptides as internal standards. We evaluated age trends in serum GDF-11 and GDF-8 concentrations in community-dwelling healthy men, 19 years or older, and determined the effects of graded testosterone doses on GDF-8 and GDF-11 concentrations in healthy men in a randomized trial. RESULTS: The assay demonstrated linearity over a wide range, lower limit of quantitation 0.5 ng/mL for both proteins, and excellent precision, accuracy, and specificity (no detectable cross-reactivity of GDF-8 in GDF-11 assay or of GDF-11 in GDF-8 assay). Mean ± SD (median ± 1QR) GDF-8 and GDF-11 levels in healthy community-dwelling men, 19 years and older, were 7.2 ± 1.9 (6.8 ± 1.4) ng/mL. Neither GDF-8 nor GDF-11 levels were related to age or body composition. Testosterone treatment significantly increased serum GDF-8 but not GDF-11 levels. CONCLUSIONS: The LC-MS/MS method for the simultaneous measurement of circulating total GDF-8 and GDF-11 demonstrates the characteristics of a valid assay. Testosterone treatment increased GDF-8 levels, but not GDF-11. Increase in GDF-8 levels by testosterone treatment, which increased muscle mass, suggests that GDF-8 acts as a chalone to restrain muscle growth.
BACKGROUND: Growth and differentiation factor (GDF)-11 controls embryonic development and has been proposed as an antiaging factor. GDF-8 (myostatin) inhibits skeletal muscle growth. Difficulties in accurately measuring circulating GDF-11 and GDF-8 have generated controversy. METHODS: We developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for simultaneous measurement of circulating GDF-8 and GDF-11 that employs denaturation, reduction, and alkylation; cation-exchange solid-phase extraction; tryptic digestion; followed by separation and quantification using 2 signature peptides for multiple reaction monitoring and C-terminal [13C615N4]-Arg peptides as internal standards. We evaluated age trends in serum GDF-11 and GDF-8 concentrations in community-dwelling healthy men, 19 years or older, and determined the effects of graded testosterone doses on GDF-8 and GDF-11 concentrations in healthy men in a randomized trial. RESULTS: The assay demonstrated linearity over a wide range, lower limit of quantitation 0.5 ng/mL for both proteins, and excellent precision, accuracy, and specificity (no detectable cross-reactivity of GDF-8 in GDF-11 assay or of GDF-11 in GDF-8 assay). Mean ± SD (median ± 1QR) GDF-8 and GDF-11 levels in healthy community-dwelling men, 19 years and older, were 7.2 ± 1.9 (6.8 ± 1.4) ng/mL. Neither GDF-8 nor GDF-11 levels were related to age or body composition. Testosterone treatment significantly increased serum GDF-8 but not GDF-11 levels. CONCLUSIONS: The LC-MS/MS method for the simultaneous measurement of circulating total GDF-8 and GDF-11 demonstrates the characteristics of a valid assay. Testosterone treatment increased GDF-8 levels, but not GDF-11. Increase in GDF-8 levels by testosterone treatment, which increased muscle mass, suggests that GDF-8 acts as a chalone to restrain muscle growth.
Authors: Xiaolan Zhou; Jin Lin Wang; John Lu; Yanping Song; Keith S Kwak; Qingsheng Jiao; Robert Rosenfeld; Qing Chen; Thomas Boone; W Scott Simonet; David L Lacey; Alfred L Goldberg; H Q Han Journal: Cell Date: 2010-08-20 Impact factor: 41.582
Authors: Steve Shiraishi; Paul W N Lee; Andrew Leung; Victor H H Goh; Ronald S Swerdloff; Christina Wang Journal: Clin Chem Date: 2008-09-18 Impact factor: 8.327
Authors: Teresa A Zimmers; Yanlin Jiang; Meijing Wang; Tiffany W Liang; Joseph E Rupert; Ernie D Au; Francesco E Marino; Marion E Couch; Leonidas G Koniaris Journal: Basic Res Cardiol Date: 2017-09 Impact factor: 17.165
Authors: Manisha Sinha; Young C Jang; Juhyun Oh; Danika Khong; Elizabeth Y Wu; Rohan Manohar; Christine Miller; Samuel G Regalado; Francesco S Loffredo; James R Pancoast; Michael F Hirshman; Jessica Lebowitz; Jennifer L Shadrach; Massimiliano Cerletti; Mi-Jeong Kim; Thomas Serwold; Laurie J Goodyear; Bernard Rosner; Richard T Lee; Amy J Wagers Journal: Science Date: 2014-05-05 Impact factor: 47.728
Authors: Francesco S Loffredo; Matthew L Steinhauser; Steven M Jay; Joseph Gannon; James R Pancoast; Pratyusha Yalamanchi; Manisha Sinha; Claudia Dall'Osso; Danika Khong; Jennifer L Shadrach; Christine M Miller; Britta S Singer; Alex Stewart; Nikolaos Psychogios; Robert E Gerszten; Adam J Hartigan; Mi-Jeong Kim; Thomas Serwold; Amy J Wagers; Richard T Lee Journal: Cell Date: 2013-05-09 Impact factor: 41.582
Authors: Richard D Semba; Pingbo Zhang; Min Zhu; Elisa Fabbri; Marta Gonzalez-Freire; Olga D Carlson; Ruin Moaddel; Toshiko Tanaka; Josephine M Egan; Luigi Ferrucci Journal: J Gerontol A Biol Sci Med Sci Date: 2019-01-01 Impact factor: 6.053
Authors: Anna L Höving; Kazuko E Schmidt; Barbara Kaltschmidt; Christian Kaltschmidt; Cornelius Knabbe Journal: Int J Mol Sci Date: 2022-08-25 Impact factor: 6.208